Close Menu

NEW YORK (GenomeWeb) – Researchers from the Phase III EURTAC study have published a secondary analysis demonstrating high sensitivity and specificity of blood-based EGFR testing compared to the initial tissue testing performed in the trial.

The study also supports growing evidence that the type of EGFR mutation a patient has, either in tumor tissue or in circulating DNA, may be associated with much different responses to the EGFR inhibitors.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Associated Press reports that a state board in Texas has asked ANDE, a maker of rapid DNA machines, to halt its work there.

James Wyngaarden, the former director of the US National Institutes of Health, has died at 94, according to Duke University School of Medicine.

Researchers find that a 30-year-old skull comes from a narwhal-beluga hybrid, according to Science News.

In Nature this week: study of value diversity in GWAS, Epstein-Barr virus subtypes linked to nasopharyngeal carcinoma risk, and more.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
24
Sponsored by
Hologic

This webinar will share the results of comparisons of commercially available nucleic acid amplification tests for use in routine screening of pregnant women for Group B Streptococcus (GBS).

Jul
25
Sponsored by
Roche

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.